Ligand Pharmaceuticals (LGND) saw its stock price plummet 5.25% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported significant losses, disappointing investors and triggering a sell-off.
According to the earnings report, Ligand posted a basic earnings per share (EPS) of -$2.21 for Q1 2025. The company's operating income came in at -$36.216 million, while its pretax profit stood at a concerning -$50.18 million. These figures paint a picture of substantial financial challenges faced by the company in the first quarter.
Despite the negative results, Ligand Pharmaceuticals has reaffirmed its financial guidance for 2025, suggesting that the company remains optimistic about its long-term prospects. However, the market's immediate reaction indicates that investors are more focused on the current performance rather than future projections. As trading continues, it remains to be seen whether Ligand can regain investor confidence and reverse this downward trend.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。